U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced plans for a nationwide advertising campaign encouraging Americans to adopt health wearables, such as heart rate and continuous glucose monitors. The initiative is part of the department’s broader “Making America Healthy Again” (MAHA) agenda.
Speaking before the House Energy and Commerce Committee’s Health Subcommittee, Kennedy emphasized the importance of personal health data. “My vision is that every American is wearing a wearable within four years,” he said. “It’s a way for people to take control of their health—seeing real-time impacts of food on glucose levels and heart rate.”
The announcement boosted shares of glucose-monitoring device makers. Dexcom (NASDAQ:DXCM) surged 10%, while Abbott gained 3.6% in afternoon trading.
Kennedy, a longtime advocate for preventive health and a critic of overreliance on pharmaceuticals, pointed to the cost-effectiveness of wearables compared to popular weight-loss drugs. “Ozempic costs $1,300 a month. If you can achieve similar results with an $80 wearable, that’s a better deal for Americans,” he noted. While he has criticized drugs like Novo Nordisk’s Ozempic, Kennedy supports their use for patients with morbid obesity or diabetes, when combined with exercise.
The campaign, which he described as one of the largest in HHS history, aims to shift the focus from reactive to proactive health management. Kennedy also hinted at exploring ways to subsidize wearables to make them more accessible.
J.P. Morgan analyst Robbie Marcus cautioned against assuming immediate changes in Medicare or insurance coverage for proactive monitoring, saying it’s too early to predict policy shifts.
The wearable tech market stands to benefit from this government push, as health monitoring tools become more mainstream in personal wellness strategies.


Federal Judge Declines to Immediately Halt Trump’s $300 Million White House Ballroom Project
Trump Taps Former DHS Official Troy Edgar for U.S. Ambassador Role in El Salvador
Sydney Bondi Beach Terror Attack Kills 16, Sparks Gun Law and Security Debate
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Trump Weighs Reclassifying Marijuana as Schedule III, Potentially Transforming U.S. Cannabis Industry
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Trump Attends Dover Ceremony Honoring U.S. Personnel Killed in Syria
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Dan Bongino to Step Down as FBI Deputy Director After Brief, Controversial Tenure
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Trump Announces $1,776 Cash Bonus for U.S. Military Personnel Ahead of Christmas
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 



